-
Zentalis Pharmaceuticals NASDAQ:ZNTL Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.
Location: 1359 Broadway, Suite 1710, NY, 10018, US | Website: www.zentalis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-180.4M
Cash
426.4M
Avg Qtr Burn
-41.59M
Short % of Float
15.03%
Insider Ownership
3.48%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Uterine disease, Cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) mono Details Cancer, Platinum-resistant ovarian cancer, Ovarian cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) +/- niraparib Details Ovarian cancer, Cancer, PARPi Resistant Ovarian Cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) comb w/ encorafenib and cetuximab Details Cancer, Metastatic colorectal cancer | Phase 1/2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Cancer, Solid tumor/s | Phase 1b Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ multiple chemo Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer | Phase 1b Update | |
Azenosertib (ZN-c3) + gemcitabine Details Cancer, Osteosarcoma | Phase 1 Update | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Ovarian cancer, Cancer, Platinum Sensitive Ovarian Cancer | Phase 1 Update | |
ZN-c5 (Oral SERD) +Verzenio® (abemaciclib) Details Breast cancer, Cancer | Failed Discontinued | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) + azenosertib Details Acute myeloid leukemia, Cancer | Failed Discontinued | |
ZN-c5: Oral SERD (Monotherapy) Details Breast cancer, Cancer | Failed Discontinued | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Cancer, relapsed or refractory light chain amyloidosis | Failed Discontinued |